Background: Chlamydophila pneumoniae (C. pneumoniae) pneumonia-associated acute respiratory distress syndrome (ARDS) is rare and has been seldom reported, but the outcome is usually fatal. This study was designed to identify the risk factors for hospitalized C. pneumoniae patients developing ARDS and to describe the outcomes. Methods: A retrospective study was performed to evaluate hospitalized patients over 18 years old diagnosed with C. pneumoniae pneumonia in a tertiary medical center. Results: Eleven patients who fulfilled the diagnostic criteria were included in this study. ARDS developed in 6 of 11 patients and mostly within 7 days of admission. Five of 6 patients needed to be transferred to the intensive care unit, and all of these patients died. The patients who developed ARDS had higher initial Acute Physiology and Chronic Health Evaluation II scores and CURB-65 (confusion, urea, respiratory rate, blood pressure, age) scores. The risk factors for developing ARDS included age ≥ 75 years, comorbid disease such as congestive heart failure, diabetes or liver cirrhosis, APACHE II score ≥ 12, CURB-65 score ≥ 2, white blood cell count > 12,000/mm 3 or < 4,000/mm 3 , serum creatinine ≥ 1.4 mg/dL, and bilateral or multilobar involvement. Conclusion: C. pneumoniae associated with ARDS has a higher mortality, and several risk factors, such as older age, underlying comorbidity and bilateral or multilobar involvement, should be identified earlier. [J Chin Med Assoc 2007; 70(8):318-323] 
Introduction
Chlamydia is now recognized as a common source of respiratory infection; most humans will have an infection at least once during their lifetime, 1 and the infection is often subclinical or mildly self-limited. The genus Chlamydophila includes Chlamydophila pneumoniae (C. pneumoniae), Chlamydophila psittaci and Chlamydophila trachomatis; C. pneumoniae has been identified as an important cause of pneumonia since the 1980s. Several studies have reported C. pneumoniae involvement in 6-20% of community-acquired pneumonia; 2, 3 the clinical picture of Chlamydia pneumonia is usually mild and prolonged. However, the course of illness, even in the elderly, is not essentially different from the course of other bacterial pneumonia infections, and severe life-threatening disease with respiratory failure requiring intensive care unit (ICU) support has seldom been reported. 4, 5 Although most severe Chlamydia pneumonia patients are elderly or have comorbid disease, several case reports of healthy adults with acute hypoxemic respiratory failure due to infection with C. pneumoniae can be found. [6] [7] [8] [9] Studies have shown that 35-47% of C. pneumoniae pneumonia is mixed with other pathogens, the most common being Streptococcus pneumoniae. [10] [11] [12] Thus, the clinical presentation may be severe and sometimes resemble bacterial pneumonia. C. pneumoniae pneumonia-associated Risk factors of Chlamydia pneumonia associated with ARDS acute respiratory distress syndrome (ARDS) is rare, but the outcome is usually fatal. An early recognition of the risk of developing ARDS could reduce this high mortality. Therefore, this study was designed to identify the risk factors for hospitalized C. pneumoniae pneumonia patients developing ARDS, and to describe the outcomes.
Methods

Patients
Between January 1995 and January 2005, patients over 18 years of age who were diagnosed with C. pneumoniae pneumonia while hospitalized in Taipei Veterans General Hospital, a tertiary medical center, were retrospectively analyzed. The diagnosis of C. pneumoniae pneumonia was based on clinical symptoms and signs (cough, fever, dyspnea, abnormal breathing sounds), radiographic findings showing new pulmonary infiltration, and microimmunofluorescence (MIF) test criteria suggested by the Centers for Disease Control and Prevention (CDC) 13 and evaluated by a College of American Pathologists-accredited laboratory. Using these criteria, 21 patients with a discharge diagnosis of C. pneumoniae pneumonia were re-evaluated, and only 5 patients who fulfilled the criteria of acute infection (IgM ≥ 1:16 or a 4-fold increase in IgG) and 6 patients who fulfilled the criteria of possible acute infection (IgG ≥ 1:512) were included in this study. The study was approved by the institutional review board of Taipei Veterans General Hospital.
Patient evaluation
In addition to the MIF test for C. pneumoniae, all patients underwent clinical and radiographic evaluation. The following variables were recorded: age, sex and underlying disease. Within 24 hours after admission, vital signs, such as systolic blood pressure, body temperature, pulse rate and respiratory rate, laboratory findings, chest radiographic features (unilateral or bilateral), and numbers of lobes involved (involvement of more than 2 lobes was defined as multilobar involvement) were recorded, as well as blood culture and sputum culture data collected within 2 days after admission, serologic tests for Mycoplasma and Legionella pneumonia, initial empiric antibiotics used, hospital days and survival status. The severity of illness was evaluated by the Acute Physiology and Chronic Health Evaluation (APACHE) II score and CURB-65 score (a 6-point score, 1 point each for confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg, age ≥ 65 years) 14 within 24 hours after admission. Patients developing acute respiratory failure with ARDS, defined by the ATS/ERS criteria, 15 comprised the ARDS group, and the others, the non-ARDS group. Arterial blood gas data, time to progression, and ICU admission data were also collected. The clinical characteristics of the ARDS group and the non-ARDS group were analyzed and compared.
Serologic test
C. pneumoniae-specific serum IgG and IgM levels were determined by the MIF method using a commercial kit (SeroFIA-Chlamydia; Savyon Diagnostics, Ashdod, Israel). Sera were tested for IgG in serial 2-fold dilutions from 1:8 to the endpoint, and in a single dilution of 1:20 for IgM. Primary infection with Chlamydia pneumoniae was defined as IgM ≥ 1:16, and re-infection was defined as IgG ≥ 1:512, or a 4-fold increase in IgG without elevation of IgM. 16 Also, all patients had negative serologic tests for Mycoplasma and Legionella pneumonia.
Statistical analysis
We compared categorical data using χ 2 statistics or Fisher's exact test, and continuous data using the Mann-Whitney U test. We assumed statistical significance for p < 0.05.
Results
Eleven patients met the CDC diagnostic criteria for acute or possibly acute C. pneumoniae infection, and ARDS developed in 6 of 11 patients, usually within 7 days of admission; only 1 patient developed ARDS on the 14 th day. Five of 6 patients needed to be transferred to the ICU, and all of these patients died (Table 1 ). All ARDS patients had higher initial APACHE II (Figure 1 ) and CURB-65 scores (Table 1) . Mixed infection with other pathogens was found in 3 of 11 patients, and they all developed ARDS within 7 days (Table 1 ) and died, although there was no statistical significance when compared to the others (p = 0.121). When analyzing the clinical data gathered within 24 hours of admission in relation to ARDS, the APACHE II score, CURB-65 score, systolic blood pressure, serum creatine, and lactate dehydrogenase all showed significant differences between the ARDS and non-ARDS groups (Table 2 ). In a further exploration of the risk factors between the 2 groups, we discovered that those aged ≥ 75 years, with underlying disease (including congestive heart failure, diabetes or liver cirrhosis), an APACHE II score ≥ 12, a CURB-65 score ≥ 2, abnormal white blood cell count (WBC > 12,000/mm 3 or < 4,000/mm 3 ), serum creatine > 1.4 mg/dL, and bilateral or multilobar radiologic involvement showed a statistically significant difference in the development of ARDS, while no difference could be found in sex, smoking history, C-reactive protein, primary infection or re-infection with C. pneumoniae, and initial treatment with appropriate antibiotics, including macrolide or quinolone (Table 3) , within 24 hours.
Discussion
C. pneumoniae pneumonia is generally considered to be a mildly infectious disease; however, severe manifestations evolving into ARDS, with high mortality, especially in the elderly, have been reported occasionally. 17 In another community-acquired pneumonia study, 6 of 25 C. pneumoniae pneumonia patients had respiratory failure; 5 were > 60 years old and had other underlying diseases. 5 In our study, 6 of 11 C. pneumoniae pneumonia patients developed ARDS, with 5 deaths; 5 of 11 C. pneumoniae pneumonia patients without ARDS all survived. The higher mortality may be attributed to the high prevalence of ARDS (6/11) and the relatively older population compared with other studies, 4,10 with a mean age of 68 years in our study. Since the MIF test had some false-negative results, and tissue culture or polymerase chain reaction assay of respiratory secretions could not be performed in this retrospective study, and given the fact that our hospital is a tertiary referral center, many mild but 
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serologically negative suspicious cases may have been treated as atypical pneumonia and underestimated in this study, causing a higher prevalence of ARDS. C. pneumoniae has been reported to cause pneumonia frequently in association with other respiratory pathogens, and mixed infection was noted in 35-47% of cases. 10, 18 Three of 11 (27%) patients in this study had mixed infection with other pathogens found by sputum cultures collected within 2 days of admission, and all of these patients died. Gram-negative bacilli and oxacillinresistant Staphylococcus were the main pathogens, and all of the patients had been admitted to other hospitals in the 3 months prior to this episode. In a previous study, 10 C. pneumoniae as a single etiology often manifested mild illness, however, mixed infection might have been the predisposing factor for ARDS and mortality. Our study found mixed infection in 50% of the ARDS group of patients, and none in the non-ARDS group, although there was no statistical significance.
The CURB-65 score is a simple tool for risk assessment of community-acquired pneumonia and has significant correlation with 30-day mortality, need for mechanical ventilation, and patients' rate of hospital admission for community-acquired pneumonia. 19 All non-ARDS group patients in this study had lower CURB-65 scores (< 2); in addition, the risk of developing ARDS was significant when CURB-65 score ≥ 2.
It seemed that the CURB-65 score also predicted the outcome of C. pneumoniae pneumonia.
In primary C. pneumoniae infection, the MIF IgM antibody is first detectable about 3 weeks after disease onset, then the IgG antibody appears 6-8 weeks later. However, in re-infection, the IgM antibody may not appear, and the IgG antibody titer quickly rises within 2 weeks. 16 Pneumonia due to Chlamydia re-infection can be more or less severe than that due to primary infection. 18 In this study, we found that primary or reinfection was not related to the development of ARDS.
Cigarette smoking has been considered to be a risk factor for C. pneumoniae infection; however, this was not seen in our study, as in others. 5 A specific finding is that the initiation of appropriate antibiotics with quinolone or macrolide did not prevent further ARDS development.
The limitations of this study include the small sample size from a single tertiary medical center, and being a retrospective review, some important factors worthy of exploration could not be explored. We did find that ARDS was a strong poor prognostic factor for Chlamydia pneumonia, and that if precipitating factors could be recognized earlier, the higher mortality of C. pneumoniae associated with ARDS might be diminished. However, these clinical significances require exploration in further prospective studies. In conclusion, C. pneumoniae patients associated with ARDS have higher mortality and ICU admission rates. The risk factors for developing ARDS when a patient is hospitalized may include an older age and higher initial APACHE II and CURB-65 scores, underlying comorbid disease, severe leukocytosis or leukopenia, impaired renal function and bilateral or multilobar involvement. 
